Spots Global Cancer Trial Database for Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Official Title: A Phase II Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib as Second-line Therapy For Patients With Advanced Hepatocellular Carcinoma.
Study ID: NCT04327700
Conditions
Study Description
Brief Summary: The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular carcinoma who have received any first line systemic therapy either standard of care Sorafenib or Lenvatinib or any experimental therapy. Patients who have received any treatment that includes either electromagnetic fields or Regorafenib will be excluded.
Detailed Description: Primary Objective: To estimate progression-free survival rates. Secondary Objectives * To obtain information concerning the feasibility of administration of the proposed treatment, including patient participation in trials using the proposed treatment. * To evaluate safety and tolerability in this patient population. * To evaluate the effect on levels of alpha-fetoprotein.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Contact Details
Name: William Blackstock, MD
Affiliation: Wake Forest University Health Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
